Other/Warning Letter·FDA Warning Letters

Warning Letter — Mineral BioSciences, LLC

MediumPublished Jul 21, 2026· AI-analyzed Jul 21, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA issued a Warning Letter to Mineral BioSciences, LLC on June 5, 2026, following an evaluation by the Human Foods Program.

Who it affects

This action affects Mineral BioSciences, LLC and potentially involves personnel responsible for food safety, quality control, and regulatory labeling within the organization.

Why it matters

The issuance of a Warning Letter by the Human Foods Program indicates significant regulatory deviations that the FDA deems necessary to address to maintain compliance. While the source provided is a summary and does not detail specific violations, such letters typically signify issues with Good Manufacturing Practices (GMP), labeling, or unapproved claims. Failure to remediate these issues can lead to further enforcement actions, including seizure or injunction.

Practical takeaway

Verify that all product claims and manufacturing processes align with Human Foods Program requirements. Regulatory and QA teams should conduct an internal audit of labeling and production documentation to ensure compliance with the specific standards cited in the Warning Letter.

FDA source material

FDA Warning Letter issued to: Mineral BioSciences, LLC. 06/05/2026 — Human Foods Program. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mineral-biosciences-llc-724745-06052026

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.